Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maitreya Medicare's yield on cost for the quarter that ended in Sep. 2023 was 0.00.
The historical rank and industry rank for Maitreya Medicare's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:MAITREYA's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.985 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Maitreya Medicare 5-Year Yield-on-Cost % Related Terms
NSE:MAITREYA vs HCA, DVA, THC: 5-Year Yield-on-Cost % Comparison
For the Medical Care Facilities subindustry, Maitreya Medicare's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maitreya Medicare 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Maitreya Medicare's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Maitreya Medicare's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Maitreya Medicare (NSE:MAITREYA) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Maitreya Medicare and its competitors.
Is Maitreya Medicare's 5-Year Yield-on-Cost % too high?
Maitreya Medicare's current 5-Year Yield-on-Cost % is 0.00. Overall, Maitreya Medicare has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Maitreya Medicare's 5-Year Yield-on-Cost % compare to HCA and DVA?
Maitreya Medicare's 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Healthcare Providers & Services industry. The industry median 5-Year Yield-on-Cost % is 2.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.99, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Maitreya Medicare and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maitreya Medicare's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maitreya Medicare stock overvalued right now?
Maitreya Medicare (NSE:MAITREYA) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Maitreya Medicare's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Maitreya Medicare (NSE:MAITREYA), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Maitreya Medicare Ltd is Multi Superspeciality hospital. It is a 125 bedded hospital that provides multi-disciplinary integrated healthcare services, with a focus on primary secondary & tertiary care, and also offers a comprehensive range of healthcare services across over 18 specialties and super specialties, including Cardiology, Urology, Oncology, Laparoscopic Surgery, Neurology, Neurosurgery, Spine Surgery, Nephrology including Dialysis, Gastroenterology, Gastrointestinal surgery, Cardiothoracic Surgery, Oncosurgery, Orthopedic Surgery including joint replacements and Arthroscopic surgeries, Gynecology & High-Risk Obstetrics, Hepatocellular Billary Surgery, Critical Care Medicine etc.
18GF Score
Get the complete analysis for NSE:MAITREYA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MAITREYA has been successfully added to your 
